肝功能障碍和心血管风险的生物标志物。
Biomarkers of Hepatic Dysfunction and Cardiovascular Risk.
机构信息
VCU Health, Department of Internal Medicine, Richmond, VA, USA.
UCD School of Medicine and Medical Science, UCD Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Dublin, Ireland.
出版信息
Curr Cardiol Rep. 2023 Dec;25(12):1783-1795. doi: 10.1007/s11886-023-01993-5. Epub 2023 Nov 16.
PURPOSE OF REVIEW
The objective of this manuscript is to examine the current literature on non-alcoholic fatty liver disease (NAFLD) biomarkers and their correlation with cardiovascular disease (CVD) outcomes and cardiovascular risk scores.
RECENT FINDINGS
There has been a growing appreciation for an independent link between NAFLD and CVD, culminating in a scientific statement by the American Heart Association in 2022. More recently, studies have begun to identify biomarkers of the three NAFLD phases as potent predictors of cardiovascular risk. Despite the body of evidence supporting a connection between hepatic biomarkers and CVD, more research is certainly needed, as some studies find no significant relationship. If this relationship continues to be robust and readily reproducible, NAFLD and its biomarkers may have an exciting role in the future of cardiovascular risk prediction, possibly as risk-enhancing factors or as components of novel cardiovascular risk prediction models.
目的综述
本文旨在探讨非酒精性脂肪性肝病（NAFLD）生物标志物的最新文献及其与心血管疾病（CVD）结局和心血管风险评分的相关性。
最近的发现
人们越来越认识到 NAFLD 与 CVD 之间存在独立联系，这最终促成了美国心脏协会在 2022 年发表的科学声明。最近的研究开始确定 NAFLD 三个阶段的生物标志物作为心血管风险的有力预测因子。尽管有大量证据支持肝生物标志物与 CVD 之间存在关联，但还需要更多的研究，因为一些研究发现两者之间没有显著关系。如果这种关系继续具有稳健性和可重复性，那么 NAFLD 及其生物标志物可能在未来的心血管风险预测中具有令人兴奋的作用，可能作为增强风险的因素或作为新型心血管风险预测模型的组成部分。
Zotero 插件